Table 2.
Synergistic effect of Amygdalin and Sorafenib against HepG2 cell growth after 48 h treatment
| Fraction Affected (Fa) |
Dose | CI a | DRI b | |||
|---|---|---|---|---|---|---|
|
Amy
(mg/ml) |
Sor
(µM) |
Amy | Sor | |||
| Combination | 0.5 | 2.03629 | 0.40726 | 0.56644 | 1.83994 | 43.5887 |
| 0.75 | 3.95499 | 0.79100 | 0.23784 | 4.26039 | 320.631 | |
| 0.9 | 7.68158 | 1.53632 | 0.10179 | 9.86495 | 2358.51 | |
| 0.95 | 12.0653 | 2.41307 | 0.05737 | 17.4625 | 9163.72 | |
| 0.97 | 16.6365 | 3.32730 | 0.03819 | 26.2164 | 24069.5 | |
Dose and effect data were obtained from the MTT assay and were analysed by CompuSyn software. This Table was created using data produced by CompuSyn Report. a Combination index (CI) was calculated from the CI equation algorithms using CompuSyn software. CI = 1, < 1 and > 1 indicates additive, synergistic and antagonistic effect, respectively. b Dose-reduction index (DRI) was calculated from the DRI equation and algorithm using CompuSyn software. DRI = 1, > 1, and < 1 indicates no, favourable, and not favourable dose-reduction, respectively, for every drug in the corresponding combination